Solid Biosciences (SLDB) COO earns 79,341 RSUs on performance milestone

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Howton David T reported acquisition or exercise transactions in this Form 4 filing.

Solid Biosciences Inc. reported that Chief Operating Officer David T. Howton received a grant of 79,341 restricted stock units (RSUs), each representing a contingent right to one share of common stock. These RSUs relate to performance stock units granted on June 11, 2024, where 25% of the target RSUs vest upon each of four predetermined performance milestones.

The Board determined that the second performance milestone was met on January 29, 2026, triggering this portion of the award. The shares tied to this milestone are scheduled to vest in the first quarter of 2027, subject to Mr. Howton’s continued service with the company on the evaluation date. This is a compensation-related equity award, not an open-market stock purchase.

Insider Trade Summary 10b5-1

1 transaction reported

Mixed 1 txn

Insider Howton David T

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	79,341	$0.00	--

Holdings After Transaction: Restricted Stock Units — 79,341 shares (Direct, null)

Footnotes (1)

Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs"). Performance stock units ("PSUs") were granted on June 11, 2024, and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the second Performance Milestone was determined by the Board to be met on January 29, 2026, and the shares related to such Performance Milestone will vest subject to the grantee's continued service with the Company on the Evaluation Date, which is anticipated to occur in the first quarter of 2027.

Key Figures

RSUs granted: 79,341 units Underlying common shares: 79,341 shares Performance milestones: 4 milestones +3 more

6 metrics

RSUs granted 79,341 units Restricted stock units awarded to COO on January 29, 2026

Underlying common shares 79,341 shares Each RSU equals one share of common stock

Performance milestones 4 milestones PSUs vest 25% of target RSUs at each milestone

Milestone portion 25% Each performance milestone vests 25% of target RSUs

Milestone achievement date January 29, 2026 Second performance milestone certified by the Board

Expected vesting period Q1 2027 Shares related to second Performance Milestone scheduled to vest

Key Terms

Restricted Stock Units, Performance stock units, Performance Milestones, non-market and non-financial in nature

4 terms

Restricted Stock Units financial

"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Performance stock units financial

"Performance stock units ("PSUs") were granted on June 11, 2024"

Performance stock units are a type of company award that grants employees shares of stock only if certain performance goals are met. They motivate employees to work toward specific company achievements, aligning their interests with those of shareholders. For investors, they can influence a company's future stock supply and reflect management’s confidence in reaching key targets.

Performance Milestones financial

"upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones")"

non-market and non-financial in nature financial

"are non-market and non-financial in nature"

Form 4 Insider Transactions: What Each Field Means →

04/21/2026 - 04:05 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Howton David T

(Last)

(First)

(Middle)

C/O SOLID BIOSCIENCES INC.

500 RUTHERFORD AVENUE, THIRD FLOOR

(Street)

CHARLESTOWN

MASSACHUSETTS

02129

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Solid Biosciences Inc. [ SLDB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
01/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	01/29/2026		A		79,341		⁽²⁾	⁽²⁾	Common Stock	79,341	$0.00	79,341	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").

2. Performance stock units ("PSUs") were granted on June 11, 2024, and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the second Performance Milestone was determined by the Board to be met on January 29, 2026, and the shares related to such Performance Milestone will vest subject to the grantee's continued service with the Company on the Evaluation Date, which is anticipated to occur in the first quarter of 2027.

	/s/ Kimberly Cornwell as attorney-in-fact for David Tyronne Howton	04/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Solid Biosciences (SLDB) report for David T. Howton?

Solid Biosciences reported that COO David T. Howton received 79,341 restricted stock units as an equity award. The grant stems from performance stock units issued June 11, 2024, after the Board certified achievement of the second performance milestone on January 29, 2026.

How many RSUs did the Solid Biosciences COO receive in this Form 4 filing?

The COO received 79,341 restricted stock units, each representing a contingent right to one share of Solid Biosciences common stock. These RSUs correspond to the portion of performance stock units that vested when the second performance milestone was determined to be met by the Board.

What are the key terms of the performance stock units disclosed by Solid Biosciences (SLDB)?

Performance stock units were granted June 11, 2024 and are tied to four independent performance milestones. Each milestone represents 25% of the target underlying RSUs, with milestones linked to non-market, non-financial business objectives certified by the Board on specified evaluation dates.

When will the 79,341 RSUs reported for Solid Biosciences’ COO vest?

The RSUs tied to the second performance milestone are scheduled to vest in the first quarter of 2027. Vesting is conditioned on the grantee’s continued service with Solid Biosciences on the evaluation date specified by the Board for this milestone.

What performance milestone triggered the RSU grant to Solid Biosciences’ COO?

The RSU grant was triggered when the Board determined the second performance milestone had been met on January 29, 2026. This milestone is based on predefined business objectives that are non-market and non-financial in nature, as set out for the performance stock units.

Is the Solid Biosciences COO’s Form 4 transaction a market purchase of SLDB shares?

No, the transaction reflects a grant of restricted stock units as compensation, not a market purchase. The RSUs arise from previously granted performance stock units that vest upon achieving specific business milestones, and will settle into common shares subject to continued service.